CLADRIBINE INJECTION 1 MG
CLADRIBINE : 1 MG · DIN 02319918 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is CLADRIBINE INJECTION?
CLADRIBINE INJECTION 1 MG contains CLADRIBINE : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02319918, held by FRESENIUS KABI CANADA LTD, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 22-Aug-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CLADRIBINE INJECTION used for?
Cladribine Injection is indicated for treatment of patients with Hairy Cell Leukemia. It should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02319918 |
|---|---|
| Brand name | CLADRIBINE INJECTION |
| Generic / active ingredient | CLADRIBINE : 1 MG |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 1 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01BB04 CLADRIBINE |
| AHFS class | 92:24.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Aug-2016 |
| Original market date | 2010-07-27 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
Is CLADRIBINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by GENERIC MEDICAL PARTNERS INC, last seen 19 Mar 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01BB04 CLADRIBINE. 2 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLADRIBINE INJECTION | 1 MG | SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | DIN 02494574 |
| LEUSTATIN 1MG/ML | 1 MG | SOLUTION | JANSSEN INC | CANCELLED POST MARKET | DIN 02022117 |
Who else supplies CLADRIBINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CLADRIBINE appears in 58 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.